Co-founder of SiteRise
RT
Rila Therapeutics
rilatx.com
Website unreachable since Oct 20, 2026
The startup develops a first-in-class small molecule allosteric inhibitor targeting HIPK2 to treat renal fibrosis, a chronic condition that leads to kidney damage. This therapy aims to provide a safe and effective anti-fibrotic solution, addressing the critical unmet medical needs of patients suffering from renal fibrosis.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a first-in-class small molecule allosteric inhibitor targeting HIPK2 to treat renal fibrosis, a chronic condition that leads to kidney damage. This therapy aims to provide a safe and effective anti-fibrotic solution, addressing the critical unmet medical needs of patients suffering from renal fibrosis.